Table of Contents

Perspectives on the history and evolution of tumor models.
Murine L1210 and P388 leukemias.
Transplantable syngeneic rodent tumors: solid tumors in mice.
B16 murine melanoma: historical perspective on the development of a solid tumor model.
Human tumor xenograft efficacy models.
Imaging the steps of metastasis at the macro and cellular level with fluorescent proteins in real time.
Patient-derived tumor models and explants.
The pediatric preclinical testing program.
Imaging efficacy in tumor models.
Mammary cancer in rats.
Animal models of melanoma.
Experimental animal models for investigating renal cell carcinoma pathogenesis and preclinical therapeutic approaches.
Animal models of mesothelioma.
The use of mouse models to study leukemia/lymphoma and assess therapeutic approaches.
Spontaneous companion animal (pet) cancers.
Genetically engineered mouse models of pancreatic ductal adenocarcinoma.
Transgenic adenocarcinoma of the mouse prostate: a validated model for the identification and characterization of molecular targets and the evaluation of therapeutic agents.
The utility of transgenic mouse models for cancer prevention research.
Models for evaluation of targeted therapies of invasive and metastatic disease.
Animal models of toxicities caused by anti-neoplastic therapy.
Bone marrow as a critical normal tissue that limits drug dose/exposure in preclinical models and the clinic.
Anesthetic considerations for the study of murine tumor models.
Preclinical tumor response end points.
Tumor cell survival.
Apoptosis in vivo.
Transparent window models and intravital microscopy: imaging gene expression, physiological function and therapeutic effects in tumors.